Department of Obstetrics and Gynecology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, 325027, P. R. China.
Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325001, P. R. China.
Adv Healthc Mater. 2023 Jul;12(17):e2202904. doi: 10.1002/adhm.202202904. Epub 2023 Mar 2.
Nanoparticles (NPs)-based drug carriers are effective in reducing systemic toxicity and drug resistance for chemotherapy, and an emerging trend focuses on integrating cell membranes with nanomedicines for tumor targeting. Mesenchymal stem cells (MSCs) are promising candidates due to their unique tropism toward cancer cells, yet the tumor-tropic abilities can differ for MSCs sourced from different tissues. Here, a multichannel microfluidic chip to screen different sourced MSCs with the greatest tropism toward cervical cancer cells is developed. Based on this, the cell membranes from the chorionic plate-derived MSC are isolated and membrane-camouflaged platinum prodrug composite NPs for cervical cancer treatment are prepared. Results demonstrate that the composite NPs can effectively target tumor sites and have a therapeutic effect both in vitro and in vivo. It is believed that the present microfluidic platform is a powerful tool for cell screening and tumor-on-a-chip studies, and the derived nanodelivery system represents the great value of cell membrane-camouflaged nanomedicine for targeted cancer therapy.
基于纳米粒子（NPs）的药物载体在降低化疗的全身毒性和耐药性方面具有显著效果，目前的一个新兴趋势是将细胞膜与纳米药物相结合，以实现肿瘤靶向。间充质干细胞（MSCs）因其对癌细胞的独特趋向性而成为有前途的候选细胞，但不同组织来源的 MSCs 的肿瘤趋向能力可能存在差异。在此，开发了一种多通道微流控芯片，用于筛选对宫颈癌细胞具有最大趋向性的不同来源的 MSCs。基于此，从胎盘膜来源的 MSC 中分离出细胞膜，并制备用于宫颈癌治疗的膜伪装顺铂前药复合纳米颗粒。结果表明，复合纳米颗粒能够有效靶向肿瘤部位，并在体外和体内均具有治疗效果。研究人员认为，本研究中的微流控平台是细胞筛选和芯片上肿瘤研究的有力工具，所衍生的纳米递药系统代表了细胞膜伪装纳米药物在肿瘤靶向治疗方面的巨大价值。
